Evoke Pharma Inc (EVOK)
0.47
+0.03
(+7.80%)
USD |
NASDAQ |
Apr 26, 16:00
0.47
0.00 (0.00%)
After-Hours: 18:38
Evoke Pharma Enterprise Value: 3.957M for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 25, 2024 | 3.957M |
April 24, 2024 | 4.054M |
April 23, 2024 | 4.020M |
April 22, 2024 | 4.118M |
April 19, 2024 | 4.232M |
April 18, 2024 | 4.320M |
April 17, 2024 | 4.915M |
April 16, 2024 | 4.245M |
April 15, 2024 | 4.289M |
April 12, 2024 | 4.584M |
April 11, 2024 | 4.839M |
April 10, 2024 | 5.156M |
April 09, 2024 | 4.754M |
April 08, 2024 | 5.008M |
April 05, 2024 | 5.223M |
April 04, 2024 | 5.391M |
April 03, 2024 | 5.517M |
April 02, 2024 | 5.456M |
April 01, 2024 | 5.262M |
March 28, 2024 | 5.432M |
March 27, 2024 | 5.235M |
March 26, 2024 | 5.387M |
March 25, 2024 | 5.262M |
March 22, 2024 | 5.364M |
March 21, 2024 | 5.262M |
Date | Value |
---|---|
March 20, 2024 | 5.288M |
March 19, 2024 | 5.424M |
March 18, 2024 | 5.517M |
March 15, 2024 | 5.517M |
March 14, 2024 | 5.980M |
March 13, 2024 | 5.695M |
March 12, 2024 | 5.771M |
March 11, 2024 | 5.814M |
March 08, 2024 | 6.195M |
March 07, 2024 | 6.153M |
March 06, 2024 | 6.026M |
March 05, 2024 | 6.017M |
March 04, 2024 | 5.898M |
March 01, 2024 | 5.771M |
February 29, 2024 | 5.872M |
February 28, 2024 | 5.517M |
February 27, 2024 | 5.608M |
February 26, 2024 | 5.601M |
February 23, 2024 | 5.696M |
February 22, 2024 | 5.932M |
February 21, 2024 | 6.017M |
February 20, 2024 | 6.109M |
February 16, 2024 | 6.026M |
February 15, 2024 | 6.195M |
February 14, 2024 | 6.248M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-2.545M
Minimum
Nov 22 2022
142.38M
Maximum
Aug 14 2020
26.47M
Average
13.67M
Median
Enterprise Value Benchmarks
Eton Pharmaceuticals Inc | 64.14M |
NovaBay Pharmaceuticals Inc | 2.275M |
Palatin Technologies Inc | 18.27M |
iBio Inc | 15.86M |
Theriva Biologics Inc | -13.19M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -1.987M |
Revenue (Quarterly) | 1.676M |
Total Expenses (Quarterly) | 3.564M |
EPS Diluted (Quarterly) | -0.59 |
Gross Profit Margin (Quarterly) | 96.48% |
Profit Margin (Quarterly) | -118.6% |
Earnings Yield | -495.7% |
Normalized Earnings Yield | -495.74 |